In this case, we found that PDT was well-tolerated and has exhibited great efficacy in synchronous CRC, especially in patients with MSI-H and POLE mutation, which would hypothetically synergize the immunotherapy-based systemic therapy (Figure 4). This evidence concerns the gene POLE and colorectal carcinoma.